AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 10451129
Drug: 0.6 mg
RxNorm normalized name: thymol 0.6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg x kg(‐1) promethazine i.m. prior to discharge
Trial: 8841149
Drug: Dihydroergotamine nasal
RxNorm normalized name: dihydroergotamine nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dihydroergotamine nasal spray
Trial: 28917229
Drug: 33 g
RxNorm normalized name: lancets 33 gauge MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 33 g peanut butter (PBG)
Trial: 28917229
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g lard (LG)
Trial: 28917229
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg [13C10] retinyl acetate capsule (reference dose) with PBG
Trial: 28917229
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg [13C10] retinyl acetate capsule (reference dose) with LG
Trial: 16489694
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg ritodrine sustained release capsules three times a day (study group, n=62)
Trial: 16489694
Drug: No treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No treatment (control group, n=58)
Trial: 14749094
Drug: Pregnenolone (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnenolone (15 mg PO per day for 2 weeks followed by 30 mg PO per day for 2 weeks)
Trial: 11338300
Drug: Benzocaine-gel preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzocaine-gel preparation (BGP)
Trial: 8197085
Drug: Three courses
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three courses of HBO therapy administered at 4 months intervals
Trial: 8197085
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (8 IDDM patients, no treatment)
Trial: 30093449
Drug: Alisertib tablets
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib tablets (60 mg/m2/dose × 7 days), irinotecan (50 mg/m2/dose i.v. × 5 days), and temozolomide (100 mg/m2/dose orally × 5 days)
Trial: 30093449
Drug: Alisertib oral
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib oral solution (45 mg/m2)
Trial: 30093449
Drug: Alisertib tablets
RxNorm normalized name: Alisertib
DrugBank: Alisertib (DB05220)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alisertib tablets (60 mg/m2/dose)
Trial: 24227801
Drug: 5 mg/mL
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/mL TID pazopanib eye drops
Trial: 24227801
Drug: 2 mg/mL
RxNorm normalized name: urea 2 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 mg/mL TID pazopanib eye drops
Trial: 24227801
Drug: 5 mg/mL
RxNorm normalized name: urea 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/mL QD pazopanib eye drops
Trial: 20434603
Drug: OnabotulinumtoxinA injections
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA injections followed by 12 weeks of postinjection task practice with FES
Trial: 20434603
Drug: OnabotulinumtoxinA injections
RxNorm normalized name: Onabotulinumtoxina
DrugBank: Botulinum toxin type A (DB00083)
FDA approved: no
EMA approved: yes
PMDA approved: yes
Description: OnabotulinumtoxinA injections followed by 12 weeks of postinjection task practice without FES
Trial: 12784106
Drug: Donepezil 5
RxNorm normalized name: donepezil 5 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Donepezil 5 mg/day for 30 days
Trial: 8780339
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch (RS2) 30 g/d
Trial: 8780339
Drug: Resistant starch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resistant starch (RS3) 30 g/d
Trial: 1361083
Drug: Formoterol (12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formoterol (12 mu/g) inhaled twice daily
Trial: 1361083
Drug: Salbutamol (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salbutamol (200 mu/g) inhaled 4 times daily
Trial: 3969207
Drug: Bromocriptine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (20 mg maximum daily dosage)
Trial: 3969207
Drug: Bromocriptine (average
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (average dosage of 13 mg)
Trial: 26953983
Drug: Watch-and-wait treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Watch-and-wait treatment (nonoperative treatment)
Trial: 18277740
Drug: Oral-B Triumph
RxNorm normalized name: Triumph
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral-B Triumph with FlossAction brush head
Trial: 16305725
Drug: Budesonide 9
RxNorm normalized name: budesonide 9 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 9 mg daily for 6 weeks
Trial: 16305725
Drug: Budesonide for
RxNorm normalized name: Budesonide
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Budesonide for treatment of clinical relapse
Trial: 11943525
Drug: Postoperative continuous
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative continuous epidural droperidol infusion (2.5 mg/day)
Trial: 11943525
Drug: Intraoperative single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative single IV injection of droperidol (2.5 mg)
Trial: 11943525
Drug: Intraoperative IV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraoperative IV injection of droperidol (2.5 mg) and postoperative continuous epidural droperidol infusion (2.5 mg/day)
Trial: 2545721
Drug: Polymyxin B
RxNorm normalized name: Polymyxin B
DrugBank: Polymyxin B (DB00781)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Polymyxin B treatment
Trial: 27966784
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual waitlist
Trial: 30556414
Drug: Desoximetasone 0.25%
RxNorm normalized name: DESOXIMETASONE 0.25% OINT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desoximetasone 0.25% spray
Trial: 21347823
Drug: Medical Treatment
RxNorm normalized name: Medical air
DrugBank: Medical air (DB09337)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical Treatment (MED)
Trial: 25306451
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of isosorbide dinitrate and hydralazine (FDC I/H)
Trial: 336052
Drug: Levamisole 100
RxNorm normalized name: Levamisole
DrugBank: Levamisole (DB00848)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Levamisole 100 mg 4 days a week for 4 months
Trial: 27692144
Drug: Salbutamol (bronchodilator)
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol (bronchodilator)
Trial: 12138347
Drug: Saquinavir soft-gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saquinavir soft-gel capsules 1200 mg three times daily + zidovudine + optional lamivudine
Trial: 6123070
Drug: lormetazepam 1
RxNorm normalized name: lormetazepam 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lormetazepam 1 mg (Noctamid)
Trial: 29524192
Drug: ChronoMag® (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ChronoMag® (100 mg magnesium element)
Trial: 29524192
Drug: Reference tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference tablet (300 mg magnesium element)
Trial: 26917334
Drug: Daily-wear CLs
RxNorm normalized name: ZINC OXIDE 22.7 g in 100 g TOPICAL LOTION [ETHICAL ZINC DAILY WEAR LIGHT SUNSCREEN SPF-50]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily-wear CLs
Trial: 24184132
Drug: Daclatasvir (60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daclatasvir (60 mg, once daily), Asunaprevir (200 mg, twice daily), BMS-791325 (75 or 150 mg, twice daily) for 12 or 24 weeks
Trial: 22971490
Drug: Bilateral superficial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral superficial cervical plexus block with 20 ml 0.5% ropivacaine
Trial: 17610807
Drug: Direct individual
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct individual therapy (SLT working individually with a child)
Trial: 17610807
Drug: Indirect individual
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect individual therapy (SLTA working individually with a child)
Trial: 17610807
Drug: Direct group
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct group therapy (SLT working with a small group of children)
Trial: 17610807
Drug: Indirect group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indirect group therapy (SLTA working with a small group of children)
Trial: 17610807
Drug: Direct therapy
RxNorm normalized name: Aleve Direct Therapy TENS Device
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Direct therapy from an SLT
Trial: 11915063
Drug: Local anesthetic
RxNorm normalized name: Local anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic (1% mepivacaine, 0.2% tetracaine, epinephrine 1:200,000) plus buprenorphine, 0.3 mg
Trial: 11915063
Drug: Local anesthetic-only
RxNorm normalized name: Gelato Anesthetic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local anesthetic-only axillary block, and IM buprenorphine 0.3 mg
Trial: 9690311
Drug: Radiotherapy combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy combined with chemotherapy (exact regimen not specified)
Trial: 9690311
Drug: Higher radiation
RxNorm normalized name: allantoin
DrugBank: Allantoin (DB11100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher radiation doses, conformal radiotherapy, altered fractionation schedules, and possibly adjuvant surgery
Trial: 9690311
Drug: New combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New combined modality strategies and new drugs
Trial: 31100155
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment using the sutured intravitreal fluocinolone acetonide implant
Trial: 31100155
Drug: Systemic treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Systemic treatment consisting of oral steroids and conventional steroid‐sparing immunosuppression
Trial: 28371205
Drug: Tofogliflozin 20
RxNorm normalized name: sotagliflozin
DrugBank: Sotagliflozin (DB12713)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Tofogliflozin 20 mg once/day
Trial: 19057513
Drug: Hydrochlorothiazide (HCT)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCT) 25 mg
Trial: 20535927
Drug: Shenqi Fuzheng
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shenqi Fuzheng Injection (SFI) combined with chemotherapy (FOLFOX protocol)
Trial: 20535927
Drug: Chemotherapy (FOLFOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (FOLFOX protocol) alone
Trial: 15574127
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of ramipril alone
Trial: 15574127
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of sildenafil alone
Trial: 15574127
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ramipril and sildenafil
Trial: 15539283
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil concentrate (FOC) 1 g/14 kg body weight/day for 4 weeks
Trial: 10535718
Drug: celiprolol 200
RxNorm normalized name: celiprolol 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: celiprolol 200 mg daily
Trial: 7786833
Drug: metoprolol 100
RxNorm normalized name: metoprolol 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: metoprolol 100 mg daily
Trial: 20938912
Drug: Narlaprevir (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narlaprevir (800 mg three times daily without ritonavir)
Trial: 20938912
Drug: Narlaprevir (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narlaprevir (400 mg twice daily with 200 mg ritonavir twice daily)
Trial: 20938912
Drug: Narlaprevir (with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Narlaprevir (with or without ritonavir) in combination with PEG‐IFN‐α‐2b
Trial: 20938912
Drug: Standard of
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care (PEG‐IFN‐α‐2b and ribavirin treatment)
Trial: 18574771
Drug: Granulocyte-colony-stimulating factor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony-stimulating factor (G-CSF) mobilization, PBMC collection by leukapheresis and PBMC transplant therapy
Trial: 18574771
Drug: Granulocyte-colony-stimulating factor
RxNorm normalized name: Granulocyte colony-stimulating factor pegfilgrastim
DrugBank: Pegfilgrastim (DB00019)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Granulocyte-colony-stimulating factor (G-CSF) mobilization for 4 days
Trial: 10412920
Drug: CoQ10 treatment
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 treatment (intravenous and intracoronary)
Trial: 10412920
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no CoQ10 treatment)
Trial: 8585104
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of 25 mg sematilide HCl
Trial: 8585104
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of 25 mg sematilide HCl
Trial: 2180144
Drug: Carbonyl iron
RxNorm normalized name: Carbonyl Iron
DrugBank: Iron (DB01592)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Carbonyl iron (100 mg orally at bedtime for 56 days)
Trial: 91432
Drug: Intensive chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intensive chemotherapy with or without cytoreductive surgery.
Trial: 31530556
Drug: Zostavax (live-attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zostavax (live-attenuated herpes zoster vaccine)
Trial: 29644582
Drug: Riluzole 200
RxNorm normalized name: Riluzole
DrugBank: Riluzole (DB00740)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Riluzole 200 mg per day for 5 weeks
Trial: 22772319
Drug: Sulfasalazine (≤
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfasalazine (≤ 3 g/day)
Trial: 9492129
Drug: Lidocaine, epinephrine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine, epinephrine, and tetracaine (LET) solution
Trial: 9492129
Drug: Placebo (sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (sterile water) solution
Trial: 8060627
Drug: Transarterial brachial
RxNorm normalized name: Brachiara mutica pollen
DrugBank: Urochloa mutica pollen (DB10716)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transarterial brachial plexus block with 60 to 70 ml of local anesthetic solution
Trial: 2493800
Drug: Oral doxapram
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral doxapram (300 mg and 600 mg)
Trial: 2493800
Drug: Morphine (0.12
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (0.12 mg kg‐1 i.m.)
Trial: 2493800
Drug: Doxapram alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram alone (300 mg and 600 mg)
Trial: 25960104
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (n = 40) conducted an oral hygiene regimen: brushing twice daily with sodium fluoride dentifrice, flossing twice daily, and mouth rinsing with anti‐cavity fluoride rinse once daily.
Trial: 23046948
Drug: Cocoa-nut cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cocoa-nut cream (CC)
Trial: 19346370
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg pafuramidine eight days before challenge
Trial: 19346370
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg pafuramidine the day before challenge
Trial: 29889239
Drug: Chloroquine (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine (25 mg base/kg over 3 days)
Trial: 3128465
Drug: Nitroglycerin infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitroglycerin infusion (200 micrograms/min)
Trial: 3128465
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of vasopressin and nitroglycerin
Trial: 31581929
Drug: Remote ischemic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remote ischemic conditioning (200 mmHg pressure, twice daily for 10-14 days)
Trial: 31581929
Drug: Guideline-based therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guideline-based therapy (control group)
Trial: 30303980
Drug: Augmented 40mcg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Augmented 40mcg HBV dose schedule
Trial: 26545149
Drug: Dexmedetomidine (group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (group D, N=25) at 0.5 µg/kg over 10 minutes, followed by an infusion at 0.5 µg/kg/h until the end of surgery
Trial: 26253520
Drug: Progressive resistance
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Progressive resistance training (PRT) with 220 g of lean red meat (raw weight) divided into two 80 g servings on training days
Trial: 23866774
Drug: Artesunate-amodiaquine (ASAQ)
RxNorm normalized name: Amodiaquine
DrugBank: Amodiaquine (DB00613)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Artesunate-amodiaquine (ASAQ) fixed-dose combination (FDC)
Trial: 21924404
Drug: Eye Movement
RxNorm normalized name: JOINT MOVEMENT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eye Movement Desensitization and Reprocessing (EMDR) therapy, average of 4.1 sessions
Trial: 18563311
Drug: nebivolol (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nebivolol (5 mg/day)
Trial: 18563311
Drug: atenolol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: atenolol (50 mg/day)
Trial: 10211538
Drug: Fluticasone propionate
RxNorm normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Fluticasone propionate 100 and 500 microg twice daily
Trial: 10211538
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 300 and 500 microg twice daily
Trial: 10211538
Drug: Oral prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone acetate (DB14646)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral prednisone 10 mg every morning
Trial: 10211538
Drug: Flunisolide 500
RxNorm normalized name: Flunisolide
DrugBank: Flunisolide acetate (DB14662)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flunisolide 500 microg twice daily
Trial: 10211538
Drug: Triamcinolone acetonide
RxNorm normalized name: Triamcinolone Acetonide
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Triamcinolone acetonide 500 microg twice daily
Trial: 8687088
Drug: AO/ASIF implants
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AO/ASIF implants
Trial: 8687088
Drug: Non‐operative treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non‐operative treatment
Trial: 2087015
Drug: AS‐4370 2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS‐4370 2.5 mg
Trial: 2087015
Drug: AS‐4370 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS‐4370 5 mg
Trial: 2087015
Drug: AS‐4370 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AS‐4370 10 mg
Trial: 6819596
Drug: Fluvoxamine (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine (150-300 mg per day)
Trial: 6819596
Drug: Chlorimipramine (150-300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorimipramine (150-300 mg per day)
Trial: 31585522
Drug: Information about
RxNorm normalized name: Inflammation OTC Bruise
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Information about treatment
Trial: 26982446
Drug: Text messaging
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Text messaging intervention for medication adherence or symptom severity
Trial: 19703761
Drug: GLA+prandial insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: GLA+prandial insulin lispro (LIS)
Trial: 19703761
Drug: GLA+prandial regular
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLA+prandial regular human insulin (RHI)
Trial: 19703761
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (LIS and RHI)
Trial: 16327946
Drug: Oral Pycnogenol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Pycnogenol
Trial: 16327946
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment (oral and local)
Trial: 2239719
Drug: Triglyceride fish
RxNorm normalized name: CAPRYLIC TRIGLYCERIDE
DrugBank: Tricaprylin (DB12176)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triglyceride fish oil (6 g/day)